欧林生物
(688319)
| 流通市值：62.55亿 | | | 总市值：62.64亿 |
| 流通股本：4.05亿 | | | 总股本：4.06亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 191,476,245.44 | 224,158,718.94 | 192,461,037.43 | 235,746,602.08 |
| 应收票据及应收账款 | 555,335,585.58 | 570,352,146.84 | 529,695,793.14 | 494,800,187.2 |
| 其中：应收票据 | 3,662,084.03 | 3,931,504.03 | 1,300,000 | 3,276,700 |
| 应收账款 | 551,673,501.55 | 566,420,642.81 | 528,395,793.14 | 491,523,487.2 |
| 预付款项 | 5,947,422.33 | 9,109,909.72 | 7,646,201.85 | 7,792,878.25 |
| 其他应收款合计 | 2,018,317.37 | 1,002,780.71 | 1,903,555.3 | 1,701,866.49 |
| 存货 | 85,147,611.63 | 85,681,980.63 | 90,441,430.49 | 85,378,518.35 |
| 其他流动资产 | 1,953,408.36 | 338,231.58 | 541,086.7 | 900,806.65 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 864,478,590.71 | 908,143,768.42 | 899,689,104.91 | 886,320,859.02 |
| 非流动资产: | | | | |
| 固定资产 | 364,288,189.66 | 359,496,159.66 | 234,256,175.55 | 239,641,113.86 |
| 在建工程 | 217,036,543.13 | 211,268,782.79 | 287,438,539 | 248,795,869.87 |
| 使用权资产 | 615,931.15 | 1,539,827.93 | 2,463,724.71 | 3,387,621.49 |
| 无形资产 | 16,029,636.95 | 16,330,201.53 | 16,072,304.66 | 16,347,484.74 |
| 开发支出 | 285,288,006.29 | 282,893,478.39 | 244,849,665.04 | 241,435,947.43 |
| 长期待摊费用 | 7,868,559.93 | 8,604,170.41 | 7,147,943.73 | 7,988,067.64 |
| 递延所得税资产 | 18,206,740.39 | 18,206,740.39 | 14,074,469.69 | 14,074,469.69 |
| 其他非流动资产 | 218,000 | 560,280 | 1,585,900 | 6,143,937 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 909,551,607.5 | 898,899,641.1 | 807,888,722.38 | 777,814,511.72 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,774,030,198.21 | 1,807,043,409.52 | 1,707,577,827.29 | 1,664,135,370.74 |
| 流动负债: | | | | |
| 短期借款 | 19,200,000 | 24,200,000 | 24,200,000 | 29,200,000 |
| 应付票据及应付账款 | 79,866,745.99 | 86,291,934.08 | 45,486,330.89 | 54,123,602.69 |
| 应付账款 | 79,866,745.99 | 86,291,934.08 | 45,486,330.89 | 54,123,602.69 |
| 合同负债 | 2,025,587.38 | 510,853.4 | 363,354.91 | 702,290.29 |
| 应付职工薪酬 | 426,394.51 | 15,196,149.64 | 458,495.15 | 404,454.73 |
| 应交税费 | 8,260,158.88 | 13,759,748.92 | 4,589,786.21 | 3,449,454.75 |
| 其他应付款合计 | 347,106,925.55 | 368,199,529.27 | 329,486,410.92 | 327,454,320.01 |
| 一年内到期的非流动负债 | 81,350,000 | 87,420,000 | 79,230,000 | 69,550,000 |
| 其他流动负债 | 60,767.62 | 15,325.6 | 13,754.85 | 21,068.71 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 538,296,579.93 | 595,593,540.91 | 483,828,132.93 | 484,905,191.18 |
| 非流动负债: | | | | |
| 长期借款 | 278,501,528.4 | 249,531,528.4 | 273,941,528.4 | 256,241,528.4 |
| 租赁负债 | 656,852.67 | 639,082 | 1,601,496.81 | 2,553,530.79 |
| 预计负债 | 744,706.38 | 532,181.34 | 731,314.42 | 698,864.84 |
| 递延收益 | 25,002,055.84 | 24,786,106.63 | 23,809,716.3 | 24,503,325.97 |
| 递延所得税负债 | 2,458,748.62 | 2,458,748.62 | 2,715,170.53 | 2,715,170.53 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 307,363,891.91 | 277,947,646.99 | 302,799,226.46 | 286,712,420.53 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 845,660,471.84 | 873,541,187.9 | 786,627,359.39 | 771,617,611.71 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 405,933,600 | 405,933,600 | 405,933,600 | 406,158,300 |
| 资本公积 | 607,911,623.63 | 606,002,585.54 | 609,254,429.51 | 613,621,844.83 |
| 减:库存股 | 5,561,325 | 5,561,325 | 5,552,337 | 7,940,898 |
| 盈余公积 | 14,198,275.26 | 14,198,275.26 | 8,615,917.45 | 8,615,917.45 |
| 未分配利润 | -102,967,913.16 | -95,894,001.38 | -107,052,309.84 | -139,025,218.63 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 919,514,260.73 | 924,679,134.42 | 911,199,300.12 | 881,429,945.65 |
| 少数股东权益 | 8,855,465.64 | 8,823,087.2 | 9,751,167.78 | 11,087,813.38 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 928,369,726.37 | 933,502,221.62 | 920,950,467.9 | 892,517,759.03 |
| 负债和股东权益合计 | 1,774,030,198.21 | 1,807,043,409.52 | 1,707,577,827.29 | 1,664,135,370.74 |
| 公告日期 | 2025-04-26 | 2025-03-29 | 2024-10-30 | 2024-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |